Low doses of antiangiogenic antibodies (anti-VEGFR2) have been shown to normalize the tumor vasculature, which improves M1-like macrophage polarization, T cell tumor infiltration, and whole-cancer-cell vaccine therapy in murine breast cancer models (136). This evidence concerns the gene KDR and neoplasm.